Phase 2 open-label extention (OLE) study of patisiran, an investigational siRNA agent for familial amyloidotic polyneuropathy (FAP)

Podobne zapisy

• Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study
  od: Suhr, Ole B, i wsp.
  Wydane: (2015)
• Diflunisal compassive use in transthyretin familial amyloidotic polyneuropathy (TTR-FAP): report of the first Spanish experience
  od: Contesse, Sebastián E Azorín, i wsp.
  Wydane: (2015)
• A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis
  od: Coelho, Teresa, i wsp.
  Wydane: (2020)
• Abnormal Heart Rate Variability and Subtle Atrial Arrhythmia in Patients with Familial Amyloidotic Polyneuropathy
  od: Wiklund, Urban, i wsp.
  Wydane: (2008)
• A study of 159 Portuguese patients with familial amyloidotic polyneuropathy (FAP) whose parents were both unaffected.
  od: Coelho, T, i wsp.
  Wydane: (1994)